Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant tislelizumab + nimotuzumab + chemotherapy for EGFR-overexpressing ESCC
ChiCTR2500099125Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, nimotuzumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanxi Cancer Hospital. Primary endpoint: pathologic complete response. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tislelizumabnimotuzumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500099125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099125.